A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
We propose to conduct a phase 2 study to assess whether the addition of acitretin to
vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC)
development, a known side effect of vemurafenib therapy, in patients with advanced melanoma.
Further, we seek a preliminary assessment as to whether the addition of acitretin to
vemurafenib enhances the clinical efficacy of this anti-melanoma agent.